IL6 and neoplasm: In pancreatic cancer patients, combining anti-Ly6G therapy to deplete neutrophils with gemcitabine/paclitaxel chemotherapy not only significantly reduced tumor burden and metastatic growth but also enhanced the functionality of tumor-infiltrating CD8+ T cells, effectively suppressed the polarization of CAF, and inhibited chemotherapy resistance via the IL-6/STAT-3 signaling pathway [206].